You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH):癲癇治療藥獲藥品註冊批件
格隆匯 04-30 18:30

格隆匯4月30日丨華海藥業(600521.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的《藥品註冊批件》。

拉莫三嗪片主要用於治療癲癇,該產品由葛蘭素史克研發,於1994年在美國上市,並於1999年在國內批准上市。拉莫三嗪片全球主要生產廠商有Teva、Lupin、Mylan等,國內生產廠商有三金集團湖南三金製藥有限責任公司。據統計,2018年拉莫三嗪製劑產品(包括全部製劑劑型)全球市場銷售額約14.6億美元(數據來源於PDB數據庫);2019年前三季度拉莫三嗪片(包括片劑、分散片)全國等級醫院銷售額約人民幣2.03億元(數據來源於鹹達數據庫)。截至目前,公司在拉莫三嗪片研發項目上已投入研發費用約人民幣760萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account